Form 4: Organogenesis Director Buys 5,000 Shares

Organogenesis Holdings Inc. Director Arthur S Leibowitz purchased 5,000 shares of Class A Common Stock at $2.681 per share.

Summary

• Arthur S Leibowitz, a Director of Organogenesis Holdings Inc. (ORGO), acquired 5,000 shares of Class A Common Stock.
• The transaction occurred on March 9, 2026, at a price of $2.681 per share.
• Following this purchase, Mr. Leibowitz directly owns 291,014 shares of Organogenesis Class A Common Stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this insider purchase as a moderately positive signal, as it demonstrates a director's confidence in the company's prospects and valuation.

Positives

• A company director, Arthur S Leibowitz, purchased 5,000 shares of Class A Common Stock, signaling confidence in the company's future prospects.
• The purchase was made at $2.681 per share, indicating a specific valuation point at which the director found the stock attractive.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-planned investment strategy rather than a reactive one.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider purchases, especially by a director, are often interpreted by the market as a positive signal, indicating management's belief in the company's intrinsic value and future growth potential. Such transactions can sometimes precede positive company developments or reflect a view that the stock is undervalued.

Related Party Transactions

• The purchase of 5,000 shares of Class A Common Stock by Director Arthur S Leibowitz is a related party transaction.

Stakeholder Impact

• Shareholders: May view the director's purchase as a positive indicator of confidence in the company's future, potentially influencing investor sentiment.

Key Dates

Recommendation

While an insider purchase by a director is generally a positive signal, indicating confidence in the company's valuation and future, it is typically not sufficient on its own to warrant a 'buy' or 'strong buy' recommendation. A 'hold' recommendation is appropriate as this transaction provides a positive data point that should be considered alongside broader financial performance, industry trends, and other fundamental analysis before making a more aggressive investment decision.

Keywords

Organogenesis, ORGO, insider transaction, stock purchase, director, beneficial ownership, Form 4, equity, 10b5-1 plan